Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials

  title={Early application of citicoline in the treatment of acute stroke: A meta-analysis of randomized controlled trials},
  author={Pei-yu Shi 石佩玉 and Xiao-cui Zhou 周小翠 and Xiao-xue Yin 尹晓雪 and Liang-liang Xu 许亮亮 and Xing-ming Zhang 张兴明 and Hong-ying Bai 白宏英},
  journal={Journal of Huazhong University of Science and Technology [Medical Sciences]},
This study was to evaluate the efficacy and safety of early application of citicoline in the treatment of patients with acute stroke by meta-analysis. Randomized controlled trials published until May 2015 were electronically searched in MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, WHO International Clinical Trial Registration Platform, Clinical Trial.gov, and China Biology Medicine disc. Two reviewers independently screened the articles and extracted the data based on… 

Neuroinflammation: friend and foe for ischemic stroke

How neuroinflammation has both beneficial as well as detrimental roles and recent therapeutic strategies to combat pathological responses are discussed and the time-dependent role of inflammatory factors could help in developing new diagnostic, prognostic, and therapeutic neuroprotective strategies for post-stroke inflammation.

Citicoline and COVID-19: vis-à-vis conjectured

This study aimed to review the potential anti-inflammatory and antioxidant effects of citicoline in the management of COVID-19 and found them to be positive.

Patogeneza udaru niedokrwiennego mózgu — możliwości neuroprotekcji i stymulowania plastyczności mózgu

Choroby naczyniowe mozgu są jedną z najczestszych przyczyn zgonu i kalectwa, a liczba zachorowan w wielu krajach świata stale wzrasta. W ostatnich latach dokonal sie duzy postep wiedzy o podstawowych



Oral Citicoline in Acute Ischemic Stroke: An Individual Patient Data Pooling Analysis of Clinical Trials

Treatment with oral citicoline within the first 24 hours after onset in patients with moderate to severe stroke increases the probability of complete recovery at 3 months, and the overall safety ofciticoline was similar to placebo.

A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke as measured by the planned analyses, and post hoc analyses suggest that a modest treatment effect may have been seen if more traditional analyses had been used.

Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases.

  • H.J. ChoY. J. Kim
  • Medicine, Psychology
    Methods and findings in experimental and clinical pharmacology
  • 2009
Oral citicoline improved neurological, functional and global outcomes in patients with acute ischemic stroke without significant safety concerns.

A randomized efficacy trial of citicoline in patients with acute ischemic stroke.

Citicoline was safe but ineffective in improving the outcome of patients with acute ischemic stroke who were enrolled in this trial, and post hoc analyses indicate that there may be a subgroup of Patients with moderate to severe strokes who would benefit.

Citicoline in Intracerebral Haemorrhage: A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Pilot Study

Citicoline seems to be a safe drug in human intracerebral haemorrhage with a positive trend regarding efficacy, and these data should be confirmed in a larger trial.

Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial.

  • F. IranmaneshA. Vakilian
  • Medicine, Psychology
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
  • 2008

Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS).

Edaravone was found to be associated with better neurological outcome at 3 months, and Citicoline's role as a neuroprotective agent however remains controversial in acute ischaemic stroke.

Therapeutic effect of Edaravone on acute cerebral infarction

Edaravone is an effective and safe medicine in the treatment of acute cerebra1 infarction and there were significant difference of all the four variables between two groups.

Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study.

A multicenter double-blind placebo-controlled study of cytidine 5'-diphosphocholine (CDP-choline) was conducted to evaluate possible clinical benefits of the drug in patients with acute, moderate to severe cerebral infarction, and CDP- choline showed significant improvements in level of consciousness compared with the placebo-treated group.